Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

GANXGANX
Showing 7 of 15 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in GAIN THERAPEUTICS INC

Yes. Citadel Advisors holds 154,524 shares of GANX (Gain Therapeutics), worth $313,684, as of its Q2 2026 13F filing. It increased the position from 24,900 shares in Q1 2026. Citadel Advisors has held GANX since Q1 2026, across 2 quarterly 13F filings.

Current Value

$313,684

Current Shares

154,524

Total Value Change

+$288,602

Total Shares Change

+142,912

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
154,524
+520.6%
$313,6840.0%$2.03
26
2026-Q1
New
24,900
-
$48,3060.0%$2.63
31
2025-Q4
Exited
0
-100.0%
$00.0%$3.05
0
2025-Q3
Increased
373,558
+130.8%
$661,1970.0%$1.81
40
2025-Q2
Increased
161,816
+750.8%
$291,2690.0%$1.97
38
2025-Q1
Increased
19,019
+63.8%
$36,3260.0%$1.89
20
2024-Q4
New
11,612
-
$25,0820.0%$2.18
29

Other major holders of GANX: GREENLIGHT CAPITAL INC, Gotham Asset Management, LLC, MARSHALL WACE, LLP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used